EVO
Evotec SEANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Primary-source updates support a real restructuring-and-cash-optionalty story: FY2025 landed at the high end of guidance, Tubulis/Gilead could add about $100 million upfront in Q2 2026, and partnered programs are still producing clinical and milestone progress [#8K-2026-04-08][#PR-2026-03-19].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
2026 guidance allows for very low EBITDA, limiting near-term downside protection.
Momentum
98
Value
41
Sentiment
56
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.00 · Bull $4.80 · Bear $2.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $5.09
Why
Momentum98 · Δ7d -
Value41 · Δ7d +0.1
Sentiment56 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
98
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
56
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 98.3 / Value 41.1 / Sentiment 55.7
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.1B
Beta
1.81
Shares Out
177.65M
P/E (TTM) · Derived
-4.7
P/S (TTM)
1.30
P/FCF (TTM) · Derived
-10.92
Rev YoY
-11.4%
EPS YoY
-8.5%
Gross Margin
+10.8%
Op Margin
-11.3%
Net Debt
$41.47M
Current Ratio
2.12
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology